A SpaceX Falcon 9 launcher destined for the International Space Station was launched last week with a smart laboratory developed by Israeli company SpacePharma, carrying among other experiments, a nanotechnology cancer treatment developed by Ayana Pharma from Jerusalem. Doxil is the first nanotechnology drug to receive FDA approval. The purpose of the experiment is to test for the first time whether there is a change in the drug itself or in its action against cancer cells under zero gravity conditions.
Prof. Yechezkel (Chezy) Barenholz, Cohort #1, founder of Ayana Pharma